SINGAPORE, Oct 17 (Bernama-BUSINESS WIRE) — Y.ora Vision, Inc., a new ophthalmic medical device company and spoke company of Eyexora, today announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a minimally invasive surgical device for the treatment of mild-to-severe open-angle glaucoma.
The licensed technology, developed by SERI researchers and co-inventors Associate Professor Shamira Perera and Professor Michael Belkin, forms the foundation of Y.ora Vision’s proprietary platform (YRA-01), based on a minimally invasive surgical (MIGS) device designed to perform multiple trabeculotomies for mild-to-severe Open Angle Glaucoma (OAG) — a next-generation surgical approach designed to lower intraocular pressure (IOP) safely, effectively, and without the need for permanent implants.